NexgenRx Reports Higher Third-Quarter Revenue, Pre-Tax Income and EBITDA
NexgenRx reported higher revenue, pre-tax income and EBITDA for the third quarter ended September 30, 2026, although income tax expense resulted in a net loss for the period.
NexgenRx Inc. reported higher revenue, income before taxes and EBITDA for the third quarter ended September 30, 2026. Revenue reached $4,904,857, income before taxes was $843,735 and EBITDA was $1,048,210, representing increases of 8%, 48.8% and 18.1%, respectively, compared with the same period in 2025.
The company said quarterly revenue rose 8.0% from the comparable period in 2025, primarily because of higher transaction fee revenue linked to increased transaction volumes and business growth. Gross profit reached $4.2 million.
Income before income taxes increased from $566,925 in the prior-year period to $843,735. NexgenRx attributed the improvement to business expansion, cost management and operational improvements.
EBITDA rose from $887,671 in the prior-year period to $1,048,210. The company said the change reflected its ability to support higher business volumes without a proportionate increase in operating expenses.
Despite the increase in pre-tax earnings, NexgenRx recorded a net loss of $63,993 for the quarter, compared with net income of $589,780 in the same period last year.
The company said the result was caused by income tax expense of $907,728, recognised as NexgenRx continued to generate taxable profits and had fully used its remaining tax loss carry-forwards. The tax expense included $716,912 in non-cash deferred income tax expense related to the recognition and use of deferred tax assets, along with $190,816 in current income tax expense.
For the nine months ended September 30, 2026, revenue increased 13.4% from the corresponding period in 2025 to $15.1 million. Net income rose 46.7% to $2.2 million, while EBITDA increased 57.9% to $3.70 million.
NexgenRx said the nine-month performance reflected the combined effects of business expansion, disciplined cost management and ongoing operational improvements.
At September 30, 2026, shareholders’ equity stood at $8.9 million. Cash and cash equivalents totalled $4.1 million, while restricted client funds held on deposit amounted to $29.6 million.
The company said its financial resources and capital management support day-to-day operations, strategic investments, future business opportunities and its ongoing dividend program.
NexgenRx identified technology modernisation, digital transformation and process automation as continuing priorities. Its Artificial Intelligence Committee has incorporated several AI-based initiatives into operations, with applications focused on workflow efficiency, analytical capabilities and decision-making.
NexgenRx describes itself as an independent full-service third-party administrator and technology solutions provider in Canada. Its services include eligibility, enrolment, hour bank and mobile access capabilities, claims adjudication and provider network coverage, delivered to Plan Sponsors through a SaaS model.
The company said its forward-looking information is subject to risks including uncertainty over whether its strategies and business plans will produce the expected benefits, the availability and cost of capital, technology development, expenditure requirements, changes in technology, laws and regulations, and cybersecurity risks. NexgenRx cautioned that actual events or results may differ materially from those anticipated.
Third-quarter revenue was $4,904,857, up 8% from the same period in 2025.
Income before taxes increased 48.8% to $843,735, while EBITDA rose 18.1% to $1,048,210.
The company reported a net loss of $63,993 after recognising $907,728 in income tax expense.
For the nine months ended September 30, 2026, revenue was $15.1 million and EBITDA was $3.70 million.
At September 30, 2026, NexgenRx reported $8.9 million in shareholders’ equity, $4.1 million in cash and cash equivalents, and $29.6 million in restricted client funds.
NexgenRx announced its financial results for the third quarter ended September 30, 2026. The company reported revenue of $4,904,857, income before taxes of $843,735 and EBITDA of $1,048,210.
NexgenRx reported third-quarter revenue of $4,904,857, an increase of 8% compared with the same period in 2025. The company said the increase was primarily attributable to higher transaction fee revenue resulting from increased transaction volumes and business growth.
NexgenRx’s income before taxes increased 48.8% to $843,735 from $566,925 in the prior-year period. The company said this reflected continued improvement in its underlying operating performance.
NexgenRx recorded a net loss of $63,993 because it recognised income tax expense of $907,728 in the quarter, compared with net income of $589,780 in the same period last year. The company said $716,912 of the tax expense was a non-cash deferred income tax expense, while $190,816 was current income tax expense, as it continued to generate taxable profits and had fully utilised its remaining tax loss carry-forwards.
NexgenRx reported third-quarter EBITDA of $1,048,210, up 18.1% from $887,671 in the prior-year period. The company said the growth in EBITDA relative to revenue demonstrated operating leverage through disciplined cost management and the ability to support higher business volumes without a proportionate increase in operating expenses.
For the nine months ended September 30, 2026, NexgenRx reported revenue of $15.1 million, up 13.4% from the corresponding period in 2025. Net income increased 46.7% to $2.2 million, while EBITDA increased 57.9% to $3.70 million.
NexgenRx said shareholders’ equity stood at $8.9 million and cash and cash equivalents totalled $4.1 million at September 30, 2026. Restricted client funds held on deposit amounted to $29.6 million, and the company said its financial resources and capital management supported day-to-day operations, strategic investments, future business opportunities and its ongoing dividend programme.
NexgenRx attributed its performance to business expansion, disciplined cost management and continued operational improvements. The company also identified technology modernisation, digital transformation and process automation as priorities intended to enhance service quality, improve productivity and create greater operating efficiencies.
NexgenRx said its Artificial Intelligence Committee had incorporated several AI-based initiatives into the company’s operations. The initiatives focus on practical applications that can improve workflow efficiency, strengthen analytical capabilities and support more informed decision-making.
Ron Loucks, NexgenRx’s President and CEO, said the company’s priorities remain sustainable expansion, operational excellence and long-term value creation. He said NexgenRx will continue allocating resources towards technology, AI-enabled capabilities and automation, while evaluating growth opportunities and balancing investment with financial performance.
NexgenRx describes itself as Canada’s only independent full-service Third-Party Administrator and Technology Solutions Provider. It offers front-end, eligibility, enrolment, hour bank and mobile access capabilities, claims adjudication and provider network coverage to Plan Sponsors through a cost-effective SaaS model.
The release identifies the TSX Venture Exchange and its Regulation Services Provider in its regulatory disclaimer. It does not provide a ticker symbol.
NexgenRx cautions that its forward-looking information is subject to risks including uncertainty over whether its strategies and business plans will deliver expected benefits, increases in sales and revenues, capital availability and cost, technology development, expenditure requirements, changes in technology, laws and regulations, cybersecurity risks and other risks disclosed in its annual Management’s Discussion and Analysis. The company states that actual events or results may differ materially from those anticipated and that it undertakes no duty to update the forward-looking information except as required by applicable securities legislation.